Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance

Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation

(2020) Jessica K. Simmons et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Sacituzumab Govitecan: First Approval

(2020) Yahiya Y. Syed   DRUGS

LILRB4-Targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia

(2020) Yasuaki Anami et al.   MOLECULAR CANCER THERAPEUTICS

Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index

(2019) Steven Coats et al.   CLINICAL CANCER RESEARCH

Engineering a HER2-specific antibody–drug conjugate to increase lysosomal delivery and therapeutic efficacy

(2019) Jeffrey C. Kang et al.   NATURE BIOTECHNOLOGY

Substrate Design Enables Heterobifunctional, Dual “Click” Antibody Modification via Microbial Transglutaminase

(2019) Joshua A. Walker et al.   BIOCONJUGATE CHEMISTRY

[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti–CTLA-4 antibody in a mouse model

(2019) Tomomi Nakayama Iwata et al.   PLoS One

Breast cancer statistics, 2019

(2019) Carol E. DeSantis et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model

(2018) Tomomi Nakayama Iwata et al.   MOLECULAR CANCER THERAPEUTICS

Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice

(2018) Yasuaki Anami et al.   Nature Communications

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

(2018) David M. Goldenberg et al.   Oncotarget

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer

(2018) Mari Hosonaga et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads

(2018) Amit Kumar et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

HER2-positive breast cancer

(2017) Sibylle Loibl et al.   LANCET

Enzymatic conjugation using branched linkers for constructing homogeneous antibody–drug conjugates with high potency

(2017) Yasuaki Anami et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates

(2016) Matthew R. Levengood et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

(2016) John Y. Li et al.   CANCER CELL

Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models

(2016) F. Li et al.   CANCER RESEARCH

Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

(2016) Yusuke Ogitani et al.   CANCER SCIENCE

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates

(2016) Heather Donaghy   mAbs

Mechanisms of Resistance to Antibody–Drug Conjugates

(2016) Frank Loganzo et al.   MOLECULAR CANCER THERAPEUTICS

Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates

(2016) Patrick J. Burke et al.   MOLECULAR CANCER THERAPEUTICS

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

(2016) Kyoji Tsuchikama et al.   Protein & Cell

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

(2015) Jessica R. McCombs et al.   AAPS Journal

In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab–MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios

(2015) Penny Bryant et al.   MOLECULAR PHARMACEUTICS

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

(2015) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading

(2015) Pavel Strop et al.   NATURE BIOTECHNOLOGY

Clinical management of breast cancer heterogeneity

(2015) Dimitrios Zardavas et al.   Nature Reviews Clinical Oncology

HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer

(2014) Hee Jin Lee et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy

(2014) Ravi V. J. Chari et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Transglutaminase-Based Chemo-Enzymatic Conjugation Approach Yields Homogeneous Antibody–Drug Conjugates

(2014) Patrick Dennler et al.   BIOCONJUGATE CHEMISTRY

Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation

(2014) Yun Shi et al.   BREAST CANCER RESEARCH

Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer

(2014) Takayasu Kurata et al.   INVESTIGATIONAL NEW DRUGS

Antibody–drug conjugates: current status and future directions

(2013) Heidi L. Perez et al.   DRUG DISCOVERY TODAY

Antibody-Dependent, Fc RI-Mediated Neutralization of HIV-1 in TZM-bl Cells Occurs Independently of Phagocytosis

(2013) L. G. Perez et al.   JOURNAL OF VIROLOGY

Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance

(2012) Hyesil Seol et al.   MODERN PATHOLOGY

CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer

(2012) T J Liu et al.   ONCOGENE

Synthesis and Evaluation of a Series of 1,2,4,5-Tetrazines for Bioorthogonal Conjugation

(2011) Mark R. Karver et al.   BIOCONJUGATE CHEMISTRY

Heterogeneity in breast cancer

(2011) Kornelia Polyak   JOURNAL OF CLINICAL INVESTIGATION

PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel

(2010) Yong Zhang et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

(2008) C. F. McDonagh et al.   MOLECULAR CANCER THERAPEUTICS